Ji Kai, Shao Yue-Juan, Hao Jian-Lei, Cheng Xian-Jiang, Guan Bing-Qing, Liu Wei-Shuai, Chen Lei, Wang Xin, Song Yong-Chun, Wang Kun, Wang Ping
Department of Pain Relief, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, and Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, and Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
J Pain Res. 2020 May 4;13:919-925. doi: 10.2147/JPR.S247303. eCollection 2020.
This study evaluated the analgesic effect of stereotactic body radiotherapy (SBRT) in combination with celiac plexus block (CPB), relative to SBRT alone, in locally advanced pancreatic cancer (LAPC) patients.
We reviewed medical records of all patients with LAPC, who received SBRT between 1 January 2017 to 31 August 2019 at our center. The average numeric rating scale (NRS) of ≥3 was used in all patients at admission. We recorded average and worst NRS in a 24-hour period, and daily narcotic doses before SBRT, followed by weekly for 1 month and monthly for 3 months.
A total of 23 patients in the SBRT group and 12 under SBRT+CPB who met the inclusion criteria were enrolled. All patients in the SBRT+CPB group received CPB within 10 days after SBRT. Pain intensity and narcotic consumption were comparable in both groups at initial assessment. However, a significant decrease ( < 0.05) in average NRS was recorded in the SBRT+CPB group relative to SBRT at 2, 3 and 4 weeks after SBRT. A comparison of daily narcotic consumption with baseline values showed a significant decrease in the SBRT+CPB group at 3 and 4 weeks after SBRT ( < 0.05), while no significant differences were observed in the SBRT group.
CPB after SBRT appears to be an effective therapeutic option in patients with LAPC and warrants further evaluation with increased number of patients in prospective clinical trials.
本研究评估了立体定向体部放疗(SBRT)联合腹腔神经丛阻滞(CPB)相对于单纯SBRT在局部晚期胰腺癌(LAPC)患者中的镇痛效果。
我们回顾了2017年1月1日至2019年8月31日在本中心接受SBRT的所有LAPC患者的病历。所有患者入院时平均数字评分量表(NRS)≥3。我们记录了24小时内的平均和最差NRS,以及SBRT前的每日麻醉剂量,随后每周记录1个月,每月记录3个月。
共纳入SBRT组23例患者和SBRT+CPB组12例符合纳入标准的患者。SBRT+CPB组的所有患者在SBRT后10天内接受了CPB。初始评估时两组的疼痛强度和麻醉药物消耗量相当。然而,相对于SBRT组,SBRT+CPB组在SBRT后2、3和4周时平均NRS显著降低(<0.05)。将每日麻醉药物消耗量与基线值进行比较,结果显示SBRT+CPB组在SBRT后3和4周时显著降低(<0.05),而SBRT组未观察到显著差异。
SBRT后行CPB似乎是LAPC患者的一种有效治疗选择,值得在前瞻性临床试验中增加患者数量进行进一步评估。